comparegroups updated: version 2.0

Size: px
Start display at page:

Download "comparegroups updated: version 2.0"

Transcription

1 comparegroups updated: version 2.0 Isaac Subirana & Joan Vila & Héctor Sanz & Judith Peñafiel & Gavin Lucas & David Giménez & & & RICAD Research on Inflammatory and Cardiovascular Disorders Program IMIM-Parc de Salut Mar, Barcelona userr! Albacete, July 10-12, 2013 Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

2 Introduction Motivation Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorĺı JV, Martínez JA, Martínez-González MA; PREDIMED Study Investigators (2013). Primary prevention of cardiovascular disease with a Mediterranean diet. New England Journal of Medicine 368(14): Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

3 Introduction Package overview comparegroups package is meant to facilitate the user to create bivariate tables in an easy and rapid way. It has a lot of parameters to change different options: decimals, reference category, report means or medians, etc. Its code is structured in classes and methods in order to make the syntax code easier (formula, update, subset,...). It is simple and short to change deafault options. A GUI has been implemented for non familiarized R users.... WUI is under development. comparegroups package (version 1.4) is available on CRAN. The present version, comparegroups 2.0 will be submitted to CRAN soon. Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

4 Introduction Other existing R packages Already existent many functions to display descriptives: summaryby [doby], stat.desc [pastecs], ctab [catspec], stat.table [Epi], tablenominal, tabledate, tablecontinuous [reporttools], summary.formula [Hmisc],... Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

5 Introduction Other existing R packages But... Some of them too much specific: only categorical or only continuous Don t mix categorical, normal (mean-sd), non-normal (quantiles) Not very intuitive to customize tables No GUI s, Difficult to add HR/OR, to deal with time-to-event variables,..., Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

6 Introduction Improvements in 2.0 version Missingness test, Improvements in current version Analysis of genetic data (SNPs), Export tables to PDF, Generation of exhaustive report to PDF file, Create plots in pdf, bmp, jpeg, png or tiff. More formats in reporting statistics: mean ± SD,..., More detailed vignette with new data set (PREDIMED), GUI improved, WUI interface to use it from a remote server, web site to recieve feed back, publish package news, etc. Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

7 How to use it 1 By syntax (full functionallity) 2 By GUI (tcltk) 3 By WUI (no R installation required) under development Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

8 Classes and methods structure functions classes methods displaying modifying print update summary subset [ plot rbind comparegroups comparegroups comparesnps* update subset rbind cbind plot createtable createtable missingtable* print summary already implemented export2: latex, csv, html, pdf report new improved Step 1: Computations Step 2: Construction Step 3: Exportation Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

9 Results On R console Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

10 Results LaTeX format MALE FEMALE No event Event No event Event HR N=2528 N=151 N=3544 N=101 Epidemiological: Age 66.0± ± [1.03;1.08] 67.6± ± [1.07;1.14] Body mass index 29.3± ± [0.97;1.06] 30.5± ± [0.94;1.04] Waist circumference 103± ± [0.99;1.02] 98.3± ± [1.00;1.03] Waist-to-height ratio 0.62± ± [0.85;205] 0.64± ± [0.89;204] History: Smoking: Never 27.0% 16.6% Ref. 87.4% 88.1% Ref. Current 24.8% 26.5% 1.63 [0.99;2.69] 5.14% 8.91% 1.94 [0.97;3.84] Former 48.2% 57.0% 1.92 [1.23;3.00] 7.51% 2.97% 0.43 [0.14;1.35] Hypertension 77.7% 79.5% 1.20 [0.81;1.79] 86.4% 89.1% 1.31 [0.70;2.46] Type-2 diabetes 52.0% 64.2% 1.59 [1.14;2.22] 43.1% 63.4% 2.12 [1.41;3.18] Dyslipidemia 66.6% 58.9% 0.81 [0.58;1.11] 77.4% 61.4% 0.52 [0.35;0.78] Family history 17.4% 14.6% 0.89 [0.57;1.41] 26.5% 28.7% 1.18 [0.77;1.82] Mediterranean diet: Intervention group: Control 29.8% 38.4% Ref. 33.6% 38.6% Ref. MedDiet + Nuts 36.7% 27.2% 0.54 [0.36;0.80] 31.1% 28.7% 0.78 [0.48;1.26] MedDiet + VOO 33.5% 34.4% 0.71 [0.49;1.03] 35.3% 32.7% 0.69 [0.43;1.10] MeDiet Adherence score 9.00 [8.00;10.0] 8.00 [7.00;10.0] 0.87 [0.81;0.94] 9.00 [7.00;10.0] 8.00 [7.00;9.00] 0.88 [0.80;0.97] HR Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

11 Results On HTML format Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

12 Plots univariate Normality plots of 'Body mass index' Barplot of 'Smoking' Histogram mean= 30.0 SD= 3.82 Normal Q Q Plot Boxplot desv. Theoretical Quantiles Sample Quantiles Standard deviation from normality Freq Never Current Former K M survival of 'tevent' survival time Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

13 Plots bivariate Boxplot of 'Body mass index' by 'Intervention group' Barplot of 'Smoking' by 'Intervention group' Freq Never Current Former Control MedDiet + Nuts MedDiet + VOO Control MedDiet + Nuts MedDiet + VOO K M survival of 'tevent' by 'Smoking' survival Never Current Former time Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

14 By syntax Select variables, type,... > res <- comparegroups(tevent ~.-toevent-event, + data = predimed, + method = c(p14 = 2), + ref.no = 'no') > res Summary of results by groups of 'tevent' var N p.value method selection 1 Intervention group ** categorical ALL 2 Sex 6324 <0.001** categorical ALL 3 Age 6324 <0.001** continuous normal ALL 4 Smoking 6324 <0.001** categorical ALL 5 Body mass index continuous normal ALL 6 Waist circumference ** continuous normal ALL 7 Waist-to-height ratio * continuous normal ALL 8 Hypertension categorical ALL 9 Type-2 diabetes 6324 <0.001** categorical ALL 10 Dyslipidemia 6324 <0.001** categorical ALL 11 Family history of premature CHD categorical ALL 12 Hormone-replacement therapy categorical ALL 13 MeDiet Adherence score 6324 <0.001** continuous non-normal ALL Signif. codes: 0 '**' 0.05 '*' 0.1 ' ' 1 Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

15 > restab <- createtable(res) By syntax Building the table No event Event N=6072 N=252 p.overall Intervention group: Control 1945 (32.0%) 97 (38.5%) MedDiet + Nuts 2030 (33.4%) 70 (27.8%) MedDiet + VOO 2097 (34.5%) 85 (33.7%) Sex: <0.001 Male 2528 (41.6%) 151 (59.9%) Female 3544 (58.4%) 101 (40.1%) Age 66.9 (6.14) 69.4 (6.65) <0.001 Smoking: <0.001 Never 3778 (62.2%) 114 (45.2%) Current 809 (13.3%) 49 (19.4%) Former 1485 (24.5%) 89 (35.3%) Body mass index 30.0 (3.81) 29.8 (3.92) Waist circumference 100 (10.6) 102 (10.6) Waist-to-height ratio 0.63 (0.07) 0.63 (0.07) Hypertension: No 1047 (17.2%) 42 (16.7%) Yes 5025 (82.8%) 210 (83.3%) Type-2 diabetes: <0.001 No 3231 (53.2%) 91 (36.1%) Yes 2841 (46.8%) 161 (63.9%) Dyslipidemia: <0.001 No 1645 (27.1%) 101 (40.1%) Yes 4427 (72.9%) 151 (59.9%) Family history of premature CHD: No 4694 (77.3%) 201 (79.8%) Yes 1378 (22.7%) 51 (20.2%) Hormone-replacement therapy: No 5341 (98.2%) 223 (99.6%) Yes 96 (1.77%) 1 (0.45%) MeDiet Adherence score 9.00 [7.00;10.0] 8.00 [7.00;10.0] <0.001 Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

16 By syntax Costumazing the table > restab <- update(restab, hide.no="no", hide=c(sex='female')) No event Event N=6072 N=252 p.overall Intervention group: Control 1945 (32.0%) 97 (38.5%) MedDiet + Nuts 2030 (33.4%) 70 (27.8%) MedDiet + VOO 2097 (34.5%) 85 (33.7%) Sex: Male 2528 (41.6%) 151 (59.9%) <0.001 Age 66.9 (6.14) 69.4 (6.65) <0.001 Smoking: <0.001 Never 3778 (62.2%) 114 (45.2%) Current 809 (13.3%) 49 (19.4%) Former 1485 (24.5%) 89 (35.3%) Body mass index 30.0 (3.81) 29.8 (3.92) Waist circumference 100 (10.6) 102 (10.6) Waist-to-height ratio 0.63 (0.07) 0.63 (0.07) Hypertension 5025 (82.8%) 210 (83.3%) Type-2 diabetes 2841 (46.8%) 161 (63.9%) <0.001 Dyslipidemia 4427 (72.9%) 151 (59.9%) <0.001 Family history of premature CHD 1378 (22.7%) 51 (20.2%) Hormone-replacement therapy 96 (1.77%) 1 (0.45%) MeDiet Adherence score 9.00 [7.00;10.0] 8.00 [7.00;10.0] <0.001 Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

17 By syntax Costumazing the table > restab <- update(restab, type = 1) No event Event N=6072 N=252 p.overall Intervention group: Control 32.0% 38.5% MedDiet + Nuts 33.4% 27.8% MedDiet + VOO 34.5% 33.7% Sex: Male 41.6% 59.9% <0.001 Age 66.9 (6.14) 69.4 (6.65) <0.001 Smoking: <0.001 Never 62.2% 45.2% Current 13.3% 19.4% Former 24.5% 35.3% Body mass index 30.0 (3.81) 29.8 (3.92) Waist circumference 100 (10.6) 102 (10.6) Waist-to-height ratio 0.63 (0.07) 0.63 (0.07) Hypertension 82.8% 83.3% Type-2 diabetes 46.8% 63.9% <0.001 Dyslipidemia 72.9% 59.9% <0.001 Family history of premature CHD 22.7% 20.2% Hormone-replacement therapy 1.77% 0.45% MeDiet Adherence score 9.00 [7.00;10.0] 8.00 [7.00;10.0] <0.001 Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

18 By syntax Costumazing the table > restab <- update(restab, show.ratio=true, show.p.overall=false) No event Event N=6072 N=252 HR p.ratio Intervention group: Control 32.0% 38.5% Ref. Ref. MedDiet + Nuts 33.4% 27.8% 0.66 [0.48;0.89] MedDiet + VOO 34.5% 33.7% 0.70 [0.53;0.94] Sex: Male 41.6% 59.9% Ref. Ref. Age 66.9 (6.14) 69.4 (6.65) 1.06 [1.04;1.09] <0.001 Smoking: Never 62.2% 45.2% Ref. Ref. Current 13.3% 19.4% 1.96 [1.40;2.74] <0.001 Former 24.5% 35.3% 2.02 [1.53;2.67] <0.001 Body mass index 30.0 (3.81) 29.8 (3.92) 0.99 [0.96;1.02] Waist circumference 100 (10.6) 102 (10.6) 1.02 [1.01;1.03] Waist-to-height ratio 0.63 (0.07) 0.63 (0.07) 5.27 [0.83;33.6] Hypertension 82.8% 83.3% 1.10 [0.79;1.53] Type-2 diabetes 46.8% 63.9% 1.88 [1.46;2.44] <0.001 Dyslipidemia 72.9% 59.9% 0.62 [0.49;0.80] <0.001 Family history of premature CHD 22.7% 20.2% 0.93 [0.68;1.26] Hormone-replacement therapy 1.77% 0.45% 0.29 [0.04;2.10] MeDiet Adherence score 9.00 [7.00;10.0] 8.00 [7.00;10.0] 0.88 [0.83;0.94] <0.001 Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

19 By syntax Costumazing the table > restab <- update(restab, show.descr=false) HR p.ratio Intervention group: Control Ref. Ref. MedDiet + Nuts 0.66 [0.48;0.89] MedDiet + VOO 0.70 [0.53;0.94] Sex: Male Ref. Ref. Age 1.06 [1.04;1.09] <0.001 Smoking: Never Ref. Ref. Current 1.96 [1.40;2.74] <0.001 Former 2.02 [1.53;2.67] <0.001 Body mass index 0.99 [0.96;1.02] Waist circumference 1.02 [1.01;1.03] Waist-to-height ratio 5.27 [0.83;33.6] Hypertension 1.10 [0.79;1.53] Type-2 diabetes 1.88 [1.46;2.44] <0.001 Dyslipidemia 0.62 [0.49;0.80] <0.001 Family history of premature CHD 0.93 [0.68;1.26] Hormone-replacement therapy 0.29 [0.04;2.10] MeDiet Adherence score 0.88 [0.83;0.94] <0.001 Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

20 By syntax Costumazing the table > males<-update(restab,x=update(res,.~.-sex,subset=sex=='male'),hide=na) > females<-update(restab,x=update(res,.~.-sex,subset=sex=='female'),hide=na) > tabcomb<-cbind("males"=males,"females"=females) Males Females HR p.ratio HR p.ratio Intervention group: Control Ref. Ref. Ref. Ref. MedDiet + Nuts 0.54 [0.36;0.80] [0.48;1.26] MedDiet + VOO 0.71 [0.49;1.03] [0.43;1.10] Age 1.06 [1.03;1.08] < [1.07;1.14] <0.001 Smoking: Never Ref. Ref. Ref. Ref. Current 1.63 [0.99;2.69] [0.97;3.84] Former 1.92 [1.23;3.00] [0.14;1.35] Body mass index 1.01 [0.97;1.06] [0.94;1.04] Waist circumference 1.01 [0.99;1.02] [1.00;1.03] Waist-to-height ratio 13.2 [0.85;205] [0.89;204] Hypertension 1.20 [0.81;1.79] [0.70;2.46] Type-2 diabetes 1.59 [1.14;2.22] [1.41;3.18] <0.001 Dyslipidemia 0.81 [0.58;1.11] [0.35;0.78] Family history of premature CHD 0.89 [0.57;1.41] [0.77;1.82] Hormone-replacement therapy Ref. Ref [0.06;2.98] MeDiet Adherence score 0.87 [0.81;0.94] [0.80;0.97] Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

21 By syntax Methods/functions on tables > varinfo(restab) --- Analyzed variable names ---- Orig varname Shown varname 1 tevent tevent 2 group Intervention group 3 sex Sex 4 age Age 5 smoke Smoking 6 bmi Body mass index 7 waist Waist circumference 8 wth Waist-to-height ratio 9 htn Hypertension 10 diab Type-2 diabetes 11 hyperchol Dyslipidemia 12 famhist Family history of premature CHD 13 hormo Hormone-replacement therapy 14 p14 MeDiet Adherence score Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

22 By syntax Methods/functions on tables > summary(restab) ---Available data---- [ALL] No event Event method select Fact OR/HR Intervention group categorical ALL -- Sex categorical ALL -- Age continuous-normal ALL 1 Smoking categorical ALL -- Body mass index continuous-normal ALL 1 Waist circumference continuous-normal ALL 1 Waist-to-height ratio continuous-normal ALL 1 Hypertension categorical ALL -- Type-2 diabetes categorical ALL -- Dyslipidemia categorical ALL -- Family history of premature CHD categorical ALL -- Hormone-replacement therapy categorical ALL -- MeDiet Adherence score continuous-non-normal ALL 1 Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

23 By syntax Methods/functions on tables > restab[1:5] Summary descriptives table by 'tevent' HR p.ratio Intervention group: Control Ref. Ref. MedDiet + Nuts 0.66 [0.48;0.89] MedDiet + VOO 0.70 [0.53;0.94] Sex: Male Ref. Ref. Age 1.06 [1.04;1.09] <0.001 Smoking: Never Ref. Ref. Current 1.96 [1.40;2.74] <0.001 Former 2.02 [1.53;2.67] <0.001 Body mass index 0.99 [0.96;1.02] Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

24 REGICOR data By syntax Missingness N=431 N=786 N=1077 p.overall Age 54.1 (11.7) 54.3 (11.2) 55.3 (10.6) Sex: Male 206 (47.8%) 390 (49.6%) 505 (46.9%) Female 225 (52.2%) 396 (50.4%) 572 (53.1%) Smoking status: <0.001 Never smoker 234 (56.4%) 414 (54.6%) 553 (52.2%) Current or former < 1y 109 (26.3%) 267 (35.2%) 217 (20.5%) Former 1y 72 (17.3%) 77 (10.2%) 290 (27.4%) Systolic blood pressure 133 (19.2) 133 (21.3) 129 (19.8) <0.001 Diastolic blood pressure 77.0 (10.5) 80.8 (10.3) 79.9 (10.6) <0.001 History of hypertension 111 (25.8%) 233 (29.6%) 379 (35.5%) <0.001 Hypertension treatment 71 (16.5%) 127 (16.2%) 230 (22.2%) Total cholesterol 225 (43.1) 224 (44.4) 213 (45.9) <0.001 HDL cholesterol 51.9 (14.5) 52.3 (15.6) 53.2 (14.2) Triglycerides 114 (74.4) 114 (70.7) 117 (76.0) LDL cholesterol 152 (38.4) 149 (38.6) 136 (39.7) <0.001 History of hyperchol. 97 (22.5%) 256 (33.2%) 356 (33.2%) <0.001 Cholesterol treatment 28 (6.50%) 68 (8.80%) 132 (12.8%) <0.001 Height (cm) 163 (9.21) 162 (9.39) 163 (9.05) Weight (Kg) 72.3 (12.6) 73.8 (14.0) 73.6 (13.9) Body mass index 27.0 (4.15) 28.1 (4.62) 27.6 (4.63) <0.001 Physical activity (Kcal/week) 491 (419) 422 (377) 351 (378) <0.001 Physical component 49.3 (8.08) 49.0 (9.63) 50.1 (8.91) Mental component 49.2 (11.3) 48.9 (11.0) 46.9 (10.8) <0.001 Cardiovascular event 10 (2.51%) 35 (4.72%) 47 (4.59%) Days to cardiovascular event or end of follow-up 1784 (1101) 1686 (1080) 1793 (1072) Overall death 18 (4.65%) 81 (11.0%) 74 (7.23%) <0.001 Days to overall death or end of follow-up 1713 (1042) 1674 (1050) 1758 (1055) Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

25 By syntax Missingness Missing table > mistab<-missingtable(regtab) N=431 N=786 N=1077 p.overall Age 0 (0.00%) 0 (0.00%) 0 (0.00%) Sex 0 (0.00%) 0 (0.00%) 0 (0.00%) Smoking status 16 (3.71%) 28 (3.56%) 17 (1.58%) Systolic blood pressure 3 (0.70%) 11 (1.40%) 0 (0.00%) <0.001 Diastolic blood pressure 3 (0.70%) 11 (1.40%) 0 (0.00%) <0.001 History of hypertension 0 (0.00%) 0 (0.00%) 8 (0.74%) Hypertension treatment 0 (0.00%) 0 (0.00%) 43 (3.99%) <0.001 Total cholesterol 28 (6.50%) 71 (9.03%) 2 (0.19%) <0.001 HDL cholesterol 30 (6.96%) 38 (4.83%) 1 (0.09%) <0.001 Triglycerides 28 (6.50%) 34 (4.33%) 1 (0.09%) <0.001 LDL cholesterol 43 (9.98%) 98 (12.5%) 27 (2.51%) <0.001 History of hyperchol. 0 (0.00%) 15 (1.91%) 6 (0.56%) Cholesterol treatment 0 (0.00%) 13 (1.65%) 42 (3.90%) <0.001 Height (cm) 8 (1.86%) 15 (1.91%) 12 (1.11%) Weight (Kg) 8 (1.86%) 15 (1.91%) 12 (1.11%) Body mass index 8 (1.86%) 15 (1.91%) 12 (1.11%) Physical activity (Kcal/week) 64 (14.8%) 22 (2.80%) 2 (0.19%) <0.001 Physical component 34 (7.89%) 123 (15.6%) 83 (7.71%) <0.001 Mental component 34 (7.89%) 123 (15.6%) 83 (7.71%) <0.001 Cardiovascular event 33 (7.66%) 45 (5.73%) 53 (4.92%) Days to cardiovascular event or end of follow-up 33 (7.66%) 45 (5.73%) 53 (4.92%) Overall death 44 (10.2%) 48 (6.11%) 54 (5.01%) Days to overall death or end of follow-up 44 (10.2%) 48 (6.11%) 54 (5.01%) Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

26 By syntax Missingness Include NA as new category: > regtab2<-update(regtab,x=update(res,include.miss=true)) N=431 N=786 N=1077 p.overall Age 54.1 (11.7) 54.3 (11.2) 55.3 (10.6) Sex: Male 206 (47.8%) 390 (49.6%) 505 (46.9%) Female 225 (52.2%) 396 (50.4%) 572 (53.1%) Smoking status: <0.001 Never smoker 234 (54.3%) 414 (52.7%) 553 (51.3%) Current or former < 1y 109 (25.3%) 267 (34.0%) 217 (20.1%) Former 1y 72 (16.7%) 77 (9.80%) 290 (26.9%) <Missing> 16 (3.71%) 28 (3.56%) 17 (1.58%) Systolic blood pressure 133 (19.2) 133 (21.3) 129 (19.8) <0.001 Diastolic blood pressure 77.0 (10.5) 80.8 (10.3) 79.9 (10.6) <0.001 History of hypertension: <0.001 Yes 111 (25.8%) 233 (29.6%) 379 (35.2%) No 320 (74.2%) 553 (70.4%) 690 (64.1%) <Missing> 0 (0.00%) 0 (0.00%) 8 (0.74%) Hypertension treatment: <0.001 No 360 (83.5%) 659 (83.8%) 804 (74.7%) Yes 71 (16.5%) 127 (16.2%) 230 (21.4%) <Missing> 0 (0.00%) 0 (0.00%) 43 (3.99%) Total cholesterol 225 (43.1) 224 (44.4) 213 (45.9) <0.001 HDL cholesterol 51.9 (14.5) 52.3 (15.6) 53.2 (14.2) Triglycerides 114 (74.4) 114 (70.7) 117 (76.0) LDL cholesterol 152 (38.4) 149 (38.6) 136 (39.7) <0.001 History of hyperchol.: <0.001 Yes 97 (22.5%) 256 (32.6%) 356 (33.1%) No 334 (77.5%) 515 (65.5%) 715 (66.4%) <Missing> 0 (0.00%) 15 (1.91%) 6 (0.56%) Cholesterol treatment: <0.001 No 403 (93.5%) 705 (89.7%) 903 (83.8%) Yes Isaac Subirana & Joan Vila (RICAD) 28 (6.50%) 68 (8.65%) comparegroups updated: version (12.3%) July 10-12, / 36

27 By syntax Exporting the table to L A TEX > export2latex(restab,"table1") to ASCII (csv) > export2csv(restab,"table1") to HTML > export2html(restab,"table1") to PDF > export2pdf(restab,"table1") Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

28 By syntax Summary of genetic data > comparesnps( ~ snp10001+snp10002+snp10003+snp snp10005+snp10006+snp10007+snp10008, SNPs) *********** Summary of genetic data (SNPs) *********** SNP Ntyped MAF Genotypes Genotypes.p HWE.p ===================================================== snp % TT TC CC snp % CC CA AA snp % GG snp % GG snp % GG GA AA snp % AA snp % CC snp % CC CG GG Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

29 GUI > cgroupsgui() Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

30 Web User Interface Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

31 Web User Interface Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

32 Web User Interface Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

33 Web User Interface Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

34 Web site comparegroups web site Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

35 Future works Future works Develop WUI and website Implement other tabular environments when exporting to L A TEX. Export to Word (explore R2wd package).... Suggestions Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

36 THANK YOU! MUCHAS GRACIAS! MOLTES GRÀCIES! Don t hesitate to contact us: Isaac Subirana < isubirana@imim.es > Joan Vila < jvila@imim.es > Isaac Subirana & Joan Vila (RICAD) comparegroups updated: version 2.0 July 10-12, / 36

New evidences of the effects of the Mediterranean diet in the prevention of cardiovascular disease

New evidences of the effects of the Mediterranean diet in the prevention of cardiovascular disease THE PREDIMED STUDY New evidences of the effects of the Mediterranean diet in the prevention of cardiovascular disease Dr. María Isabel Covas Cardiovascular Risk and Nutrition Research Group The REGICOR

More information

MA Martínez-González.

MA Martínez-González. MA Martínez-González Coordinador RD 06/0045 PREDIMED (Alimentación saludable en la prevención primaria de enfermedades crónicas) www.unav.es/preventiva Estrategia Estructura organizativa Trabajo en red

More information

Effects of polyphenol intake on cardiovascular risk markers

Effects of polyphenol intake on cardiovascular risk markers Effects of polyphenol intake on cardiovascular risk markers OMICS: Advances, Applications and Translation in Nutrition and Epidemiology Boston, May 30, 2017 Rosa M. Lamuela-Raventós Departament of Nutrition,

More information

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution of A: total cholesterol (TC); B: low-density lipoprotein

More information

La Dieta Mediterrània en la DM2. L estudi Predimed

La Dieta Mediterrània en la DM2. L estudi Predimed Dr. María-Isabel Covas Cardiovascular Risk and Nutrition Research Group The REGICOR Study Group IMIM Hospital del Mar Research Institut Barcelona Spain CIBER de Fisiopatología de la Obesidad y Nutrición

More information

Table S1. Characteristics associated with frequency of nut consumption (full entire sample; Nn=4,416).

Table S1. Characteristics associated with frequency of nut consumption (full entire sample; Nn=4,416). Table S1. Characteristics associated with frequency of nut (full entire sample; Nn=4,416). Daily nut Nn= 212 Weekly nut Nn= 487 Monthly nut Nn= 1,276 Infrequent or never nut Nn= 2,441 Sex; n (%) men 52

More information

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Know Your Number Aggregate Report Single Analysis Compared to National Averages Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and weight change with cardiovascular disease among people with and without diabetes. JAMA. doi:10.1001/jama.2013.1644.

More information

NORTH SOUTH UNIVERSITY TUTORIAL 1

NORTH SOUTH UNIVERSITY TUTORIAL 1 NORTH SOUTH UNIVERSITY TUTORIAL 1 REVIEW FROM BIOSTATISTICS I AHMED HOSSAIN,PhD Data Management and Analysis AHMED HOSSAIN,PhD - Data Management and Analysis 1 DATA TYPES/ MEASUREMENT SCALES Categorical:

More information

PROOF. (not for distribution)

PROOF. (not for distribution) THELANCETDE-D-16-00306R1 S2213-8587(16)30085-7 Embargo: June 6, 2016 [23:30] BST Effect of a high-fat Mediterranean diet on bodyweight and waist circumference: a prespecified secondary outcomes analysis

More information

The Mediterranean Diet: The Optimal Diet for Cardiovascular Health

The Mediterranean Diet: The Optimal Diet for Cardiovascular Health The Mediterranean Diet: The Optimal Diet for Cardiovascular Health Vasanti Malik, ScD Research Scientist Department of Nutrition Harvard School of Public Health Cardiovascular Disease Prevention International

More information

Overview. The Mediterranean Diet: The Optimal Diet for Cardiovascular Health. No conflicts of interest or disclosures

Overview. The Mediterranean Diet: The Optimal Diet for Cardiovascular Health. No conflicts of interest or disclosures The Mediterranean Diet: The Optimal Diet for Cardiovascular Health No conflicts of interest or disclosures Vasanti Malik, ScD Research Scientist Department of Nutrition Harvard School of Public Health

More information

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up... Study Population: 340... Total Population: 500... Time Window of Baseline: 09/01/13 to 12/20/13... Time Window of Follow-up:

More information

DM type. Diagnostic method of DR. fluorescein angiography; Ophthalmoscopy. ophthalmoscopic examination. fundus photography; Ophthalmoscopy

DM type. Diagnostic method of DR. fluorescein angiography; Ophthalmoscopy. ophthalmoscopic examination. fundus photography; Ophthalmoscopy 2012 Informa USA, Inc. DOI: 10.3109/13816810.2012.675398 Online supplementary material published in conjunction with S. Zhao et al.., Nitric oxide synthase 3 (NOS3) 4b/a, T-786C and G894T polymorphisms

More information

A European model for the Automatic Production of Standardized Performance Indicators: the BIRO statistical engine

A European model for the Automatic Production of Standardized Performance Indicators: the BIRO statistical engine EUropean Best Information through Regional Outcomes in Diabetes A European model for the Automatic Production of Standardized Performance Indicators: the BIRO statistical engine Fabrizio Carinci Serectrix

More information

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values

More information

Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts

Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts Original Article Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts R. Estruch, E. Ros, J. Salas Salvadó, M.-I. Covas, D. Corella, F.

More information

Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms

Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Men (%) 20 (55) 54 (67) 0.216 Age (years) 57 ± 10 56 ±

More information

InterestinhowmicroRNAscanbeusedinthepreventionand treatment of cardiovascular disease (CVD) 4 has increased over

InterestinhowmicroRNAscanbeusedinthepreventionand treatment of cardiovascular disease (CVD) 4 has increased over MicroRNA-410 regulated lipoprotein lipase variant rs13702 is associated with stroke incidence and modulated by diet in the randomized controlled PREDIMED trial 1 3 Dolores Corella, Jose V Sorlí, Ramon

More information

Epidemiologic Measure of Association

Epidemiologic Measure of Association Measures of Disease Occurrence: Epidemiologic Measure of Association Basic Concepts Confidence Interval for population characteristic: Disease Exposure Present Absent Total Yes A B N 1 = A+B No C D N 2

More information

Your health is a crucial aspect of your life. That s why the Yakima Heart Center offers this booklet; to help you identify the numbers that affect

Your health is a crucial aspect of your life. That s why the Yakima Heart Center offers this booklet; to help you identify the numbers that affect Your health is a crucial aspect of your life. That s why the Yakima Heart Center offers this booklet; to help you identify the numbers that affect your health and well-being. Knowing your medical history

More information

Welch Allyn ABPM 6100S. Comprehensive blood pressure monitoring that brings patient comfort home.

Welch Allyn ABPM 6100S. Comprehensive blood pressure monitoring that brings patient comfort home. Welch Allyn ABPM 6100S Comprehensive blood pressure monitoring that brings patient comfort home. Features and Benefits of the Welch Allyn ABPM 6100S Pictorial application instructions, artery markers and

More information

BLOODPRESSURE & PULSE App for iphone, ipad and ipod USER GUIDE. App Version 2.2

BLOODPRESSURE & PULSE App for iphone, ipad and ipod USER GUIDE. App Version 2.2 App for iphone, ipad and ipod USER GUIDE App Version 2.2 Table of contents Description 3-4 Views 5 Enter your measurements 6 Summary of your values 7 Stages of Hypertension 8 Statistics 9-10 Diary Logs

More information

DC , Revision 2. Overall Diet History and Reversibility of the Metabolic Syndrome Over 5 Years: The Whitehall II Prospective Cohort Study

DC , Revision 2. Overall Diet History and Reversibility of the Metabolic Syndrome Over 5 Years: The Whitehall II Prospective Cohort Study May 2010 DC09-2200, Revision 2 Overall Diet History and Reversibility of the Metabolic Syndrome Over 5 Years: The Whitehall II Prospective Cohort Study Running Title: Overall Diet and Reversion of Metabolic

More information

Mediterranean Diet and Cardiovascular Health: Teachings of the PREDIMED Study 1 3

Mediterranean Diet and Cardiovascular Health: Teachings of the PREDIMED Study 1 3 SUPPLEMENT Proceedings of the IUNS 20th Congress of Nutrition Mediterranean Diet and Cardiovascular Health: Teachings of the PREDIMED Study 1 3 Emilio Ros, 4,6 *MiguelA.Martínez-González, 6,7 Ramon Estruch,

More information

CVD Prevention, Who to Consider

CVD Prevention, Who to Consider Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..

More information

To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees.

To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees. E Nancy A. Haller, MPH, CHES, Manager, State Wellness Program M PLOYEES To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees. To suspend or decrease the rising costs

More information

Prevention of Diabetes With Mediterranean Diets A Subgroup Analysis of a Randomized Trial

Prevention of Diabetes With Mediterranean Diets A Subgroup Analysis of a Randomized Trial Annals of Internal Medicine Original Research Prevention of Diabetes With Mediterranean Diets A Subgroup Analysis of a Randomized Trial Jordi Salas-Salvadó, MD, PhD*; Mònica Bulló, PhD; Ramón Estruch,

More information

Qualification Form Instructions

Qualification Form Instructions Qualification Form Instructions Congratulations on taking steps toward maintaining or improving your health! The Blue Cross Blue Shield of Michigan qualification form is enclosed for you and your physician

More information

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li

More information

Page 1. Disclosures. Background. No disclosures

Page 1. Disclosures. Background. No disclosures Population-Based Lipid Screening in the Era of a Childhood Obesity Epidemic: The Importance of Non-HDL Cholesterol Assessment Brian W. McCrindle, Cedric Manlhiot, Don Gibson, Nita Chahal, Helen Wong, Karen

More information

The Clinical Information Data Entry Screen is the main screen in the DQCMS application.

The Clinical Information Data Entry Screen is the main screen in the DQCMS application. DATA ENTRY Clinical Information The Clinical Information Data Entry Screen is the main screen in the DQCMS application. To enter data, a patient must first be selected from the Patient pull-down list.

More information

Frequency of nut consumption and mortality risk in the PREDIMED nutrition intervention trial

Frequency of nut consumption and mortality risk in the PREDIMED nutrition intervention trial Guasch-Ferré et al. BMC Medicine 2013, 11:164 RESEARCH ARTICLE Open Access Frequency of nut consumption and mortality risk in the PREDIMED nutrition intervention trial Marta Guasch-Ferré 1,2, Mònica Bulló

More information

SUPPLEMENTARY MATERIAL

SUPPLEMENTARY MATERIAL SUPPLEMENTARY MATERIAL The effect of current dietary provided by frequent advice versus food delivery on weight loss and cardiovascular risk factors. A Randomized Clinical Trial. David JA Jenkins, Beatrice

More information

University of Groningen. Metabolic risk in people with psychotic disorders Bruins, Jojanneke

University of Groningen. Metabolic risk in people with psychotic disorders Bruins, Jojanneke University of Groningen Metabolic risk in people with psychotic disorders Bruins, Jojanneke IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from

More information

Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic

More information

Qualification Form Instructions

Qualification Form Instructions Qualification Form Instructions Congratulations on taking steps toward maintaining or improving your health! The Blue Cross Blue Shield of Michigan Qualification Form is enclosed for you and your physician

More information

Depok-Indonesia STEPS Survey 2003

Depok-Indonesia STEPS Survey 2003 The STEPS survey of chronic disease risk factors in Indonesia/Depok was carried out from February 2003 to March 2003. Indonesia/Depok carried out Step 1, Step 2 and Step 3. Socio demographic and behavioural

More information

The Mediterranean Diet decreases LDL atherogenicity in high cardiovascular risk

The Mediterranean Diet decreases LDL atherogenicity in high cardiovascular risk The Mediterranean Diet decreases LDL atherogenicity in high cardiovascular risk individuals: a randomized controlled trial Álvaro Hernáez 1,2,3, Olga Castañer 1,3, Alberto Goday 1,3, Emilio Ros 3,4, Xavier

More information

ORIGINAL INVESTIGATION. Effect of a Mediterranean Diet Supplemented With Nuts on Metabolic Syndrome Status

ORIGINAL INVESTIGATION. Effect of a Mediterranean Diet Supplemented With Nuts on Metabolic Syndrome Status ORIGINAL INVESTIGATION Effect of a Mediterranean Diet Supplemented With Nuts on Metabolic Syndrome Status One-Year Results of the PREDIMED Randomized Trial Jordi Salas-Salvadó, MD, PhD; Joan Fernández-Ballart,

More information

RELATIONSHIP OF CLINICAL FACTORS WITH ADIPONECTIN AND LEPTIN IN CHILDREN WITH NEWLY DIAGNOSED TYPE 1 DIABETES. Yuan Gu

RELATIONSHIP OF CLINICAL FACTORS WITH ADIPONECTIN AND LEPTIN IN CHILDREN WITH NEWLY DIAGNOSED TYPE 1 DIABETES. Yuan Gu RELATIONSHIP OF CLINICAL FACTORS WITH ADIPONECTIN AND LEPTIN IN CHILDREN WITH NEWLY DIAGNOSED TYPE 1 DIABETES by Yuan Gu BE, Nanjing Institute of Technology, China, 2006 ME, University of Shanghai for

More information

CARE PATHWAYS. Allyson Ashley

CARE PATHWAYS. Allyson Ashley CARE PATHWAYS Allyson Ashley WHAT IS A CARE PATHWAY? An explicit statement of the goals and key elements of care based on evidence, best practice, and patient s expectations and their characteristics The

More information

2/11/2017. Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox. Disclosures. Carl J. Lavie, MD, FACC, FACP, FCCP

2/11/2017. Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox. Disclosures. Carl J. Lavie, MD, FACC, FACP, FCCP Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox Carl J. Lavie, MD, FACC, FACP, FCCP Professor of Medicine Medical Director, Cardiac Rehabilitation and Preventive Cardiology

More information

Mississippi Stroke Systems of Care

Mississippi Stroke Systems of Care Stroke Initiatives Mississippi State Department of Health Cassandra Dove, Chronic Disease Bureau 19 th Annual Stroke Belt Consortium March 1, 2014 Mississippi Stroke Systems of Care Heart Disease and Stroke

More information

Dietary fat intake and risk of cardiovascular disease and all-cause mortality in a population at high risk of cardiovascular disease 1

Dietary fat intake and risk of cardiovascular disease and all-cause mortality in a population at high risk of cardiovascular disease 1 Dietary fat intake and risk of cardiovascular disease and all-cause mortality in a population at high risk of cardiovascular disease 1 Marta Guasch-Ferré, 2,3 Nancy Babio, 2,3 Miguel A Martínez-González,

More information

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to

More information

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,

More information

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for

More information

Cardiovascular Disease Risk Behaviors of Nursing Students in Nursing School

Cardiovascular Disease Risk Behaviors of Nursing Students in Nursing School International Journal of Medical Research & Health Sciences Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2018, 7(8): 16-33 I J M R

More information

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation.

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure

More information

National Collaborative Wave 2 (Wave 9): National Diabetes Prevention and Management Wave, Month 9 Diabetes Management: Diabetes Register

National Collaborative Wave 2 (Wave 9): National Diabetes Prevention and Management Wave, Month 9 Diabetes Management: Diabetes Register National Collaborative Wave 2 (Wave 9): National Diabetes Prevention and Management Wave, Month 9 Diabetes Management: Diabetes Register The above graph shows a decrease in the number of patients on the

More information

Reduction in the Incidence of Type 2-Diabetes with the Mediterranean Diet: Results of the PREDIMED-Reus Nutrition Intervention Randomized Trial

Reduction in the Incidence of Type 2-Diabetes with the Mediterranean Diet: Results of the PREDIMED-Reus Nutrition Intervention Randomized Trial Diabetes Care Publish Ahead of Print, published online October 13, 2010 Reduction in the Incidence of Type 2-Diabetes with the Mediterranean Diet: Results of the PREDIMED-Reus Nutrition Intervention Randomized

More information

Screening Results. Juniata College. Juniata College. Screening Results. October 11, October 12, 2016

Screening Results. Juniata College. Juniata College. Screening Results. October 11, October 12, 2016 Juniata College Screening Results Juniata College Screening Results October 11, 2016 & October 12, 2016 JUNIATA COLLEGE The J.C. Blair Hospital CARES team screened 55 Juniata College employees on October

More information

Mediterranean diet, retinopathy and nephropathy microvascular diabetes complications:

Mediterranean diet, retinopathy and nephropathy microvascular diabetes complications: Mediterranean diet, retinopathy and nephropathy microvascular diabetes complications: A post hoc analysis of a randomized trial Andrés Díaz-López, RD 1,2 ; Nancy Babio, BSc, PhD 1,2 ; Miguel A Martínez-González,

More information

Mediterranean Diet Pattern and Health

Mediterranean Diet Pattern and Health NUTRI-BITES Webinar Series Mediterranean Diet Pattern and Health will begin at the top of the hour Audio for today s presentation is being broadcast over your computer speakers, so be sure they are turned

More information

Andrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University

Andrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University CARDIOVASCULAR RISK FACTORS ORIGINAL ARTICLE Do We Correctly Assess the Risk of Cardiovascular Disease? Characteristics of Risk Factors for Cardiovascular Disease Depending on the Sex and Age of Patients

More information

Supplemental Table 1 Age and gender-specific cut-points used for MHO.

Supplemental Table 1 Age and gender-specific cut-points used for MHO. Supplemental Table 1 Age and gender-specific cut-points used for MHO. Age SBP (mmhg) DBP (mmhg) HDL-C (mmol/l) TG (mmol/l) FG (mmol/l) Boys 6-11 90th * 90th * 1.03 1.24 5.6 12 121 76 1.13 1.44 5.6 13 123

More information

The increasing incidence of type 2 diabetes

The increasing incidence of type 2 diabetes Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Reduction in the Incidence of Type 2 Diabetes With the Mediterranean Diet Results of the PREDIMED-Reus nutrition intervention

More information

Nutrition Care Process. Catherine Villafranca & Anthony Richitt

Nutrition Care Process. Catherine Villafranca & Anthony Richitt Nutrition Care Process Catherine Villafranca & Anthony Richitt Nutrition Care Process -According to eatrightpro.org, the Nutrition Care Process is a systematic approach to providing high-quality nutrition

More information

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular

More information

Mediterranean Diet and Cardiodiabesity: A Review

Mediterranean Diet and Cardiodiabesity: A Review Nutrients 2014, 6, 3474-3500; doi:10.3390/nu6093474 Review OPEN ACCESS nutrients ISSN 2072-6643 www.mdpi.com/journal/nutrients Mediterranean Diet and Cardiodiabesity: A Review Elena García-Fernández 1,2,

More information

Predictors of short- and long-term adherence with a Mediterranean-type diet intervention: the PREDIMED randomized trial

Predictors of short- and long-term adherence with a Mediterranean-type diet intervention: the PREDIMED randomized trial Downer et al. International Journal of Behavioral Nutrition and Physical Activity (2016) 13:67 DOI 10.1186/s12966-016-0394-6 RESEARCH Open Access Predictors of short- and long-term adherence with a Mediterranean-type

More information

SUPPLEMENTAL MATERIAL. Materials and Methods. Study design

SUPPLEMENTAL MATERIAL. Materials and Methods. Study design SUPPLEMENTAL MATERIAL Materials and Methods Study design The ELSA-Brasil design and concepts have been detailed elsewhere 1. The ELSA-Brasil is a cohort study of active or retired 15,105 civil servants,

More information

Overweight and Obesity in Older Persons: Impact Upon Health and Mortality Outcomes

Overweight and Obesity in Older Persons: Impact Upon Health and Mortality Outcomes Overweight and Obesity in Older Persons: Impact Upon Health and Mortality Outcomes Gordon L Jensen, MD, PhD Senior Associate Dean for Research Professor of Medicine and Nutrition Objectives Health outcomes

More information

Supplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups

Supplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups Supplemental Table S1: Unadjusted and Adjusted Hazard Ratios for Diabetes Associated with Baseline Factors Considered in Model 3 SMART Participants Only Unadjusted Adjusted* Baseline p-value p-value Covariate

More information

Correlation of novel cardiac marker

Correlation of novel cardiac marker Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely

More information

The Metabolic Syndrome: Is It A Valid Concept? YES

The Metabolic Syndrome: Is It A Valid Concept? YES The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA

More information

Metabolic Syndrome.

Metabolic Syndrome. www.bmiweightloss.com.au What is the metabolic syndrome? The was first described in 1988 by Gerald Reavson It was originally described as the clustering of four conditions These conditions when present

More information

Information Management in General Practice

Information Management in General Practice Information Management in General Practice Using PEN Clinical Audit Tool Training Workbook for General Practice Written by Noel Stewart March 2010 Workbook and Training Course for General Practice Acknowledgments:

More information

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015 Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015 Presentation downloaded from http://ce.unthsc.edu Objectives Understand that the obesity epidemic is also affecting children and adolescents

More information

Professor Clare Collins

Professor Clare Collins Dietary Patterns and Cardiovascular Disease (CVD) Outcomes: An evidence summary Professor Clare Collins PhD, BSc, Dip Nutr&Diet, Dip Clin Epi, advapd, FDAA Director of Research, School of Health Sciences,

More information

Methods. Background and Objectives STRADIVARIUS

Methods. Background and Objectives STRADIVARIUS STRADIVARIUS Effect of on Progression of Atherosclerosis in Patients with Abdominal Obesity and Coronary Artery Disease Steven E. Nissen MD Stephen J. Nicholls MBBS PhD, Kathy Wolski MPH, Josep Rodés-Cabau

More information

Heart Health. Team Member Workbook Session 1 LEARN IDENTIFY ACT. Learn about HTHU Level 3 and the point system

Heart Health. Team Member Workbook Session 1 LEARN IDENTIFY ACT. Learn about HTHU Level 3 and the point system LEARN Learn about HTHU Level 3 and the point system 01 IDENTIFY Identify the major risk factors for cardiovascular disease and how to improve our cardiovascular health 03 02 ACT Begin our Session 1 Goal

More information

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,

More information

Positive Change for Life

Positive Change for Life Positive Change for Life Dr Sharon Avery, Project lead on behalf of the Alfred Late Effects Clinic, on behalf of the Alfred Late Effects Clinic, Leukaemia Foundation and Southern Melbourne Integrated Cancer

More information

ASSeSSing the risk of fatal cardiovascular disease

ASSeSSing the risk of fatal cardiovascular disease ASSeSSing the risk of fatal cardiovascular disease «Systematic Cerebrovascular and coronary Risk Evaluation» think total vascular risk Assess the risk Set the targets Act to get to goal revised; aupril

More information

Risk Factors for Heart Disease

Risk Factors for Heart Disease Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress

More information

Director, Employee Health & Productivity. Coordinator, Employee Health & Productivity

Director, Employee Health & Productivity. Coordinator, Employee Health & Productivity Director, Employee Health & Productivity Coordinator, Employee Health & Productivity Table 2:. ChartE: Female HDL Cholesterol Risk Levels Optimal Borderline High Risk 80% 60% 40% 20% 0% LDL Cholesterol

More information

Why are NICE guidelines and standards important and relevant to us?

Why are NICE guidelines and standards important and relevant to us? Why are NICE guidelines and standards important and relevant to us? Dr Liz England GP, Laurie Pike health centre RCGP Mental Health Clinical and Commissioning Lead SWB CCG Mental Health Lead NIHR Clinical

More information

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,

More information

Why Screen at 23? What can YOU do?

Why Screen at 23? What can YOU do? Why Screen at 23? Every 1 in 2 Asian American adults has diabetes or prediabetes. More than half of Asian Americans did not know they have type 2 diabetes or prediabetes. Asian Americans can develop diabetes

More information

Mediterranean Diet: Miracle or Mirage. Edwin Cox, M.D.

Mediterranean Diet: Miracle or Mirage. Edwin Cox, M.D. Mediterranean Diet: Miracle or Mirage Edwin Cox, M.D. The Mediterranean Diet Unique Distinction The only major diet whose effectiveness has been demonstrated in controlled trials In subjects with a first

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL Supplemental Table 1. Distribution of Participants Characteristics by Treatment Group at Baseline - The Vitamin D and calcium (CaD) Trial of the Women s Health Initiative (WHI) Study,

More information

MOLINA HEALTHCARE OF CALIFORNIA

MOLINA HEALTHCARE OF CALIFORNIA MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel

More information

Intro to R. Professor Clayton Nall h/t Thomas Leeper, Ph.D. (University of Aarhus) and Teppei Yamamoto, Ph.D. (MIT) June 26, 2014

Intro to R. Professor Clayton Nall h/t Thomas Leeper, Ph.D. (University of Aarhus) and Teppei Yamamoto, Ph.D. (MIT) June 26, 2014 Intro to R Professor Clayton Nall h/t Thomas Leeper, Ph.D. (University of Aarhus) and Teppei Yamamoto, Ph.D. (MIT) June 26, 2014 Nall Intro to R 1 / 44 Nall Intro to R 2 / 44 1 Opportunities 2 Challenges

More information

LEPTIN AS A NOVEL PREDICTOR OF DEPRESSION IN PATIENTS WITH THE METABOLIC SYNDROME

LEPTIN AS A NOVEL PREDICTOR OF DEPRESSION IN PATIENTS WITH THE METABOLIC SYNDROME LEPTIN AS A NOVEL PREDICTOR OF DEPRESSION IN PATIENTS WITH THE METABOLIC SYNDROME Diana A. Chirinos, Ronald Goldberg, Elias Querales-Mago, Miriam Gutt, Judith R. McCalla, Marc Gellman and Neil Schneiderman

More information

for the Management of Chronic Disease

for the Management of Chronic Disease Patient-Centred Care Approaches for the Management of Chronic Disease Anna Chapman Research Fellow RDNS Institute Overview of Presentation Burden Second of level Disease in Australia Chronic Disease Management

More information

Client Report Screening Program Results For: Missouri Western State University October 28, 2013

Client Report Screening Program Results For: Missouri Western State University October 28, 2013 Client Report For: Missouri Western State University October 28, 2013 Executive Summary PROGRAM OVERVIEW From 1/1/2013-9/30/2013, Missouri Western State University participants participated in a screening

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content McEvoy JW, Chen Y, Ndumele CE, et al. Six-year change in high-sensitivity cardiac troponin T and risk of subsequent coronary heart disease, heart failure, and death. JAMA Cardiol.

More information

Health First. New Health Bucks Program MANATEE YOURCHOICE HEALTH PLAN

Health First. New Health Bucks Program MANATEE YOURCHOICE HEALTH PLAN Health First New Health Bucks Program MANATEE YOURCHOICE HEALTH PLAN www.manateeyourchoice.com/healthfirst A special thanks to Aetna for covering the printing costs of this booklet. CONTENTS OUR PURPOSE

More information

Understanding the metabolic syndrome

Understanding the metabolic syndrome Understanding the metabolic syndrome Understanding the metabolic system Metabolic syndrome is the clustering together of a number of risk factors for heart disease, stroke and diabetes. Having one of these

More information

Author, year Study Location Outcome(s) Exposure n Follow-up Results/observations. MedDiet rich in alpha-linolenic diet vs usual post-infarct prudent

Author, year Study Location Outcome(s) Exposure n Follow-up Results/observations. MedDiet rich in alpha-linolenic diet vs usual post-infarct prudent SUPPLEMENTAL MATERIAL Table 3. Main prospective observational studies and randomized controlled trials published until May 2017, assessing the effects of the Mediterranean diet on from or incidence of

More information

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of

More information

The Mediterranean Diet improves HDL function in high cardiovascular risk

The Mediterranean Diet improves HDL function in high cardiovascular risk The Mediterranean Diet improves HDL function in high cardiovascular risk individuals: a randomized controlled trial Álvaro Hernáez, PharmD, MSc 1,2,3 ; Olga Castañer, MD, PhD 1,3 ; Roberto Elosua, MD,

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia

More information

Letter to the Editor. Association of TCF7L2 and GCG Gene Variants with Insulin Secretion, Insulin Resistance, and Obesity in New-onset Diabetes *

Letter to the Editor. Association of TCF7L2 and GCG Gene Variants with Insulin Secretion, Insulin Resistance, and Obesity in New-onset Diabetes * 814 Biomed Environ Sci, 2016; 29(11): 814-817 Letter to the Editor Association of TCF7L2 and GCG Gene Variants with Insulin Secretion, Insulin Resistance, and Obesity in New-onset Diabetes * ZHANG Lu 1,^,

More information

Mediterranean diet score and total and cardiovascular mortality in Eastern Europe: the HAPIEE study

Mediterranean diet score and total and cardiovascular mortality in Eastern Europe: the HAPIEE study DOI 10.1007/s00394-015-1092-x ORIGINAL CONTRIBUTION Mediterranean diet score and total and cardiovascular mortality in Eastern Europe: the HAPIEE study Denes Stefler 1 Sofia Malyutina 2 Ruzena Kubinova

More information

Is Knowing Half the Battle? Behavioral Responses to Risk Information from the National Health Screening Program in Korea

Is Knowing Half the Battle? Behavioral Responses to Risk Information from the National Health Screening Program in Korea Is Knowing Half the Battle? Behavioral Responses to Risk Information from the National Health Screening Program in Korea Hyuncheol Bryant Kim 1, Suejin A. Lee 1, and Wilfredo Lim 2 1 Cornell University

More information

Effective Interventions in the Clinical Setting: Engaging and Empowering Patients. Michael J. Bloch, M.D. Doina Kulick, M.D.

Effective Interventions in the Clinical Setting: Engaging and Empowering Patients. Michael J. Bloch, M.D. Doina Kulick, M.D. Effective Interventions in the Clinical Setting: Engaging and Empowering Patients Michael J. Bloch, M.D. Doina Kulick, M.D. UNIVERSITY OF NEVADA SCHOOL of MEDICINE Sept. 8, 2011 Reality check: What could

More information